Eli Lilly's India obesity campaign halt resurfaces, months after regulator scrutiny
Resurfacing a May 2026 move, Lilly paused an India obesity-awareness campaign after regulators flagged potential indirect promotion of Mounjaro, adding uncertainty to disease-awareness marketing as drugmakers target the country's fast-growing weight-management market.
What happened
Eli Lilly halted its India obesity-awareness campaign after drug-regulator scrutiny over potential indirect promotion of Mounjaro. The action creates
Key facts
- India obesity market projected at ₹8,000 crore ($839.37 million) annually by 2030
- Current India obesity market valuation: ₹1,734 crore
- 24% of women aged 15-49 were overweight or obese in 2019-2021
- Nearly 23% of men aged 15-54 were overweight or obese in 2019-2021
- Mounjaro launched in India in March 2025
What changed
Eli Lilly halted its India obesity-awareness campaign after drug-regulator scrutiny over potential indirect promotion of Mounjaro. The action creates uncertainty for disease-awareness marketing as Lilly and Novo Nordisk compete in India’s fast-growing obesity-treatment market.
Why this matters
Treat India disease-awareness marketing as a high-compliance channel: separate education from product cues, tighten review workflows and prepare for campaign interruptions.
What to watch
- A formal regulator notice, fine, guidance, or rule defining indirect prescription-drug promotion.
- Whether Lilly restarts the campaign and the wording, channels, and partners used in its replacement.
- Enforcement actions involving Novo Nordisk, local GLP-1 marketers, telehealth platforms, pharmacies, or influencers.
- Restrictions on digital health advertising, online prescription fulfillment, or obesity-clinic marketing.
- India launch timing, pricing, supply availability, and prescription uptake for Mounjaro and competing obesity treatments.